Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols

Blood (2012) 120 (21): 4785.

https://doi.org/10.1182/blood.V120.21.4785.4785

Published: 2012

Journal Articles

Comparison of Short-Term Outcomes Between CSTIBES02 and ALL Ph08 Trials for Young Patients with Philadephia Chromosome-Positive ALL (Ph+ALL) Differing In Imatinib Dose and Amount of Chemotherapy Before Stem Cell Transplantation

Blood (2011) 118 (21): 2582.

https://doi.org/10.1182/blood.V118.21.2582.2582

Published: 2011

Journal Articles

Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience

Pere Barba, Antonia Sampol, MD, María Calbacho, Jose Gonzalez, MD, Josefina Serrano, Pilar Martinez-Sanchez, MD, Pascual Fernandez, MD., Raimundo Garcia-Boyero, MD, Rodrigo Martino, MD, PhD, Pilar Delgado, MD, Jose Angel Hernandez-rivas, MD, Eloy Del Potro, MD, Soledad Gonzalez-Muñiz, MD, MAria Isabel Gomez-Sanchez, MD, Adolfo de la Fuente, MD, Javier Bueno, Josep-Maria Ribera, MD, PhD

Blood (2011) 118 (21): 4246.

https://doi.org/10.1182/blood.V118.21.4246.4246

Published: 2011

Journal Articles

Specific Chemotherapy and Rituximab In HIV-Infected Patients with Burkitt's Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors

Blood (2010) 116 (21): 3944.

https://doi.org/10.1182/blood.V116.21.3944.3944

Published: 2010

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.

Blood (2009) 114 (22): 322.

https://doi.org/10.1182/blood.V114.22.322.322

Published: 2009

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.

Blood (2008) 112 (11): 3291.

https://doi.org/10.1182/blood.V112.11.3291.3291

Published: 2008

Journal Articles

The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph−) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.

Isabel Granada, MD, Juan-Manuel Sancho, MD, Albert Oriol, MD, Mireia Morgades, MD, Concepción Bethencourt, MD, Ricardo Parody, MD, Jesús-María Hernández-Rivas, PhD, Maria-José Moreno, MD, Eloy Del-Potro, MD, Mar Tormo, MD, Concepción Rivas, MD, Miguel-Angel Sanz, PhD, Carlos Grande, MD, Javier Bueno, MD, Eugenia Abella, MD, Juan-José Ortega, PhD, Josep-Maria Ribera, PhD

Blood (2007) 110 (11): 3501.

https://doi.org/10.1182/blood.V110.11.3501.3501

Published: 2007

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.

Blood (2006) 108 (11): 1872.

https://doi.org/10.1182/blood.V108.11.1872.1872

Published: 2006

Journal Articles

Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.

Juan-Manuel Sancho, MD, Josep-Maria Ribera, PhD, Albert Oriol, MD, Jesus-Maria Hernandez-Rivas, PhD, Concepcion Rivas, MD, Concepcion Bethencourt, MD, Javier Fernández-Calvo, MD, Ricardo Parody, MD, Guillermo Deben, MD, Jose-Luis Bello, MD, Josep-Maria Marti, MD, Eugenia Abella, PhD, Eloy Del-Potro, MD, Maria-Jose Terol, MD, Evarist Feliu, PhD

Blood (2005) 106 (11): 1841.

https://doi.org/10.1182/blood.V106.11.1841.1841

Published: 2005

Journal Articles

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Josep-Maria Ribera, PhD, Juan-Jose Ortega, MD, Albert Oriol, MD, Pilar Bastida, MD, Carlota Calvo, MD, Jose-María Perez-Hurtado, MD, Maria-Elvira González-Valentin, MD, Vicky Martin-Reina, MD, Antonio Molines, MD, Fernando Ortega-Rivas, MD, Maria-Pilar Queipo, MD, Concepción Rivas, MD, Izaskun Egurbide, MD, Inmaculada Heras, MD, Concepción Poderos, MD, Eva Martínez-Revuelta, MD, Jose-Maria Guinea, MD, Eloy del Potro, MD, Guillermo Deben, MD

Blood (2005) 106 (11): 173.

https://doi.org/10.1182/blood.V106.11.173.173

Published: 2005

Journal Articles

Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate.

Josep-Maria Ribera, MD, Albert Oriol, MD, Marcos Gonzalez, MD, Maria-Belen Vidriales, MD, Blanca Xicoy, MD, Javier Grau, MD, Jordi Esteve, MD, Salut Brunet, MD, Eloy Del Potro, MD, Maria-Jose Moreno, MD, Mar Tormo, MD, Maria-Victoria Martin-Reina, MD, Guillermo Deben, MD, Ricardo Parody, MD, Juan-Jose Lahuerta, MD, Jesus-Fernando San Miguel, MD

Blood (2004) 104 (11): 4483.

https://doi.org/10.1182/blood.V104.11.4483.4483

Published: 2004

Journal Articles

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Josep-Maria Ribera, MD, Albert Oriol, MD, Concepcion Bethencourt, MD, Ricardo Parody, MD, Jesus-Maria Hernandez-Rivas, MD, Maria-Jose Moreno, MD, Eloy Del Potro, MD, Mar Tormo, MD, Concepcion Rivas, MD, Joan Besalduch, MD, Miguel-Angel Sanz, MD, Jesus Arias, MD, Javier Fernandez-Calvo, MD, Jose-Maria Moraleda, MD, Javier Bueno, MD, Evarist Feliu, MD, Juan-Jose Ortega, MD

Blood (2004) 104 (11): 2731.

https://doi.org/10.1182/blood.V104.11.2731.2731

Published: 2004

NARROW

Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols

Comparison of Short-Term Outcomes Between CSTIBES02 and ALL Ph08 Trials for Young Patients with Philadephia Chromosome-Positive ALL (Ph+ALL) Differing In Imatinib Dose and Amount of Chemotherapy Before Stem Cell Transplantation

Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience

Specific Chemotherapy and Rituximab In HIV-Infected Patients with Burkitt's Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.

The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph−) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.

Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Children with Very High-Risk Acute Lymphoblastic Leukemia (VHR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate.

Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL). Final Results of the PETHEMA ALL-93 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only